B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CRYAB

MOLECULAR TARGET

crystallin alpha B

UniProt: P02511NCBI Gene: 14101 compounds

CRYAB (crystallin alpha B) is targeted by 1 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CRYAB

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Lanosterol0.691

About CRYAB as a Drug Target

CRYAB (crystallin alpha B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 1 compounds with documented CRYAB interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CRYAB inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.